As November is Asbestos Awareness Month many councils and stakeholder groups across Australia support this campaign by holding events to raise awareness of the dangers of asbestos. On Tuesday 22nd November the ADRI presented lunch time information sessions to Concord Hospital staff not only to raise awareness of the dangers of asbestos but to also
The Board of the Asbestos Diseases Research Foundation (ADRF) is pleased to announce that Prof Ken Takahashi has been appointed as the new ADRI Director. He will take over from Prof Nico van Zandwijk – the Institute’s inaugural Director who has held the position since 2008 – in February of 2017. Ken Takahashi is Professor
The first results from the MesomiR 1 trial, a phase I clinical trial of a targeted delivery of a microRNA-based therapy, were published yesterday in the American Journal of Respiratory and Critical Care Medicine The trial is a collaboration between ADRI, the Sydney-based biotech company EnGeneIC Ltd and three hospitals in Sydney. The treatment consists
The Dr. J. Stumphius Recognition Award, sponsored by Shield Group International, was awarded to Prof. Nico van Zandwijk (ADRI) for his groundbreaking discovery in treating the asbestos cancer called mesothelioma, providing hope and saving lives of untold many people. The award, showing a glass plate on a bronze base, signifying a heavy burden shared by
Researchers from ADRI were well represented at the recent International Mesothelioma Interest Group (iMig) Conference, which was held from 21-24 October in Cape Town. A large number of presentations were made, including 7 short talks and 5 posters, reflecting the broad spectrum of research carried out at ADRI. Find details of the program here, and
A study led by ADRI Researcher Dr Anthony Linton has recently appeared in the British Journal of Cancer. The article explores the clinical, pathological and treatment factors associated with prolonged survival in malignant pleural mesothelioma. In a large series of 910 patients registered with the NSW Dust Diseases Board, the prognostic impact of age, gender,
The Cancer Institute NSW Premier’s Awards for Outstanding Cancer Research is an annual event that celebrates excellence and innovation in cancer research. Seven awards were presented on Friday, August 22, to those leading the way in their field. Dr Glen Reid, from the Asbestos Disease Research Institute, accepted one of the awards – the Excellence in
The research leading to ADRI’s upcoming clinical trial has been recognised by the award of one of two best poster prizes at the recent WIN Symposium 2014 in Paris. The study describes the translational research leading to the new microRNA-based treatment approach for malignant pleural mesothelioma and non-small cell lung cancer, and was presented by
Following on from last year’s breakthrough research into the role of microRNAs in malignant pleural mesothelioma, Dr Glen Reid has been awarded a $346,000 grant from the Cancer Council NSW to further ADRI’s research into microRNA-based replacement therapy. One of just 16 applications funded this year, the project entitled “Developing a microRNA-based drug as a
Australian scientists, inventors and surgeons worked together in ground-breaking research that has lead to the discovery of a way to slow down the growth of deadly asbestos-related cancer malignant pleural mesothelioma. The break-through underpins a clinical trial due to start in six weeks.
More than 10,000 Australians have died since the early 1980s, with more than 25,000 expected to die over the next four decades, because of mesothelioma, an asbestos-related cancer. The cancer can take up to 40 years to develop.
This year’s finals of the Concord Repatriation General Hospital Early Career Research Awards were held on 22nd and 29th of October at the ANZAC Research Institute. These yearly research prizes are co-sponsored by Concord Hospital and the ANZAC Research Institute and awarded to early career researchers who primarily undertake their work on Concord Hospital Campus.
Asbestos is the generic term used for a number of silicate minerals with fibrous crystalline structures. For more than 4,500 years naturally occurring fibrous minerals have been used by humans for their flexibility, strength, chemical inertness and insulation qualities. The Romans used asbestos for its flame-retardant and insulation properties by weaving asbestos fibers into fabrics